CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the Company’s Board of Directors, effective November 8, 2019. Dr. Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and business leader in the biotechnology, therapeutics and medical device industries. With the addition of Dr. Rosenthal, InVivo’s Board has six members, five of whom are independent.
“Dr. Rosenthal’s deep experience across a range of corporate functions, from corporate development and business operations, to strategic planning and capital market transactions, will be a highly valuable addition to our Board as we guide the Company forward toward its near- and long-term goals,” said Ann Merrifield, InVivo’s Chair of the Board of Directors.
Dr. Rosenthal currently serves as Chairman of the Board of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, where from 2014 to 2018 he also served as Chief Executive Officer. Dr. Rosenthal also currently serves as a director of the Bruker Corporation, a publicly traded manufacturer of analytic instruments, since 2015. Dr. Rosenthal has served since 2007 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as Chairman of its board of directors since May 2016. He also currently serves as a director of Galvanic Applied Sciences, Inc., a privately-held Canadian company, since 2013.
“I am excited to join the InVivo Board at this critical period in the company’s history, and I look forward to working together with the Board and the InVivo team as InVivo continues advancing down its clinical pathway to ultimately address an area of significant unmet need for spinal cord injury patients,” commented Dr. Rosenthal.
Dr. Rosenthal has more than 25 years of experience in a variety of senior management positions with companies involved in the development of therapeutics, medical devices, diagnostics and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc.
Dr. Rosenthal holds a Ph.D. from Emory University and a Master of Science degree from the State University of New York.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the expectations related to continued progress with and updates from InVivo’s clinical pathway, corporate development and strategic planning. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and its other filings with the SEC, including the Company’s Form 10-K, Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.
